CTRB1 and type 1 diabetes mellitus: Yazdanpanah et al. used proteome-wide Mendelian randomization to identify signal regulatory protein γ (SIRPG), interleukin-27 Epstein-Barr virus–induced 3 (IL27.EBI3) and chymotrypsinogen B1 (CTRB1) as potential drug targets for T1D treatment [113].